Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
Gil Yosipovitch(University of Miami), Thomas A. Luger(University Hospital Münster), Anke Beselin(Eli Lilly (Germany)), Lovisa Berggren(Eli Lilly (Germany)), M. Dossenbach, Martin Steinhoff(Cornell University), Carsten Henneges(Eli Lilly (Germany)), Adam Reich(Rzeszów University of Technology), Toby Kent(Eli Lilly (United Kingdom))
Cited by 23
Related Papers
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Tachykinins and Their Receptors: Contributions to Physiological Control and the Mechanisms of Disease
|Physiological Reviews|2014|611